Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July...
Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform
Nona Biosciences announced on July 23, 2026 a strategic research collaboration with the Medical University...
Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub
Private enterprises from Pakistan and China have signed nine pharmaceutical sector agreements valued at approximately...
AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial
AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah...
MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG: 2252) issued a positive profit alert announcing its...
CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial...
PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial...
Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...
OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient...
Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma
Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic...
Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring
Former President Donald Trump announced on July 21, 2026 a three-phase tariff policy on generic...
GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced on July 22, 2026 that the U.S. Food and...
Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer
Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug...
Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced positive results from a Phase 2a...
Johnson & Johnson Secures FDA De Novo Authorization for OTTAVA™ – World’s First Table-Integrated Robotic Surgical System
Johnson & Johnson (NYSE: JNJ) announced on July 22, 2026 that the U.S. Food and...
Guangdong Launches Greater Bay Area Cross-Border Medical Import Framework for Hong Kong and Macau Pharmaceuticals
The Guangdong Provincial Drug Administration and Guangdong Provincial Health Commission have issued the Guidelines for...
China Announces 12th National Drug Volume-Based Procurement with Enhanced Pricing Mechanism and Expanded Participation
The National Joint Procurement Office announced on July 22, 2026 that the 12th batch of...
Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...
Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a RMB 300 million (approximately...